TRUEBLUE INC (TBI) Fundamental Analysis & Valuation

NYSE:TBI • US89785X1019

Current stock price

3.33 USD
-0.13 (-3.76%)
At close:
3.35 USD
+0.02 (+0.6%)
After Hours:

This TBI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TBI Profitability Analysis

1.1 Basic Checks

  • TBI had negative earnings in the past year.
  • TBI had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: TBI reported negative net income in multiple years.
  • In multiple years TBI reported negative operating cash flow during the last 5 years.
TBI Yearly Net Income VS EBIT VS OCF VS FCFTBI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -7.51%, TBI is doing worse than 73.26% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -17.47%, TBI is doing worse than 69.77% of the companies in the same industry.
Industry RankSector Rank
ROA -7.51%
ROE -17.47%
ROIC N/A
ROA(3y)-9.23%
ROA(5y)-3.13%
ROE(3y)-20.15%
ROE(5y)-7.08%
ROIC(3y)N/A
ROIC(5y)N/A
TBI Yearly ROA, ROE, ROICTBI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30

1.3 Margins

  • The Gross Margin of TBI (22.76%) is worse than 68.60% of its industry peers.
  • In the last couple of years the Gross Margin of TBI has remained more or less at the same level.
  • TBI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.19%
GM growth 5Y-0.94%
TBI Yearly Profit, Operating, Gross MarginsTBI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. TBI Health Analysis

2.1 Basic Checks

  • TBI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TBI has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for TBI has been reduced compared to 5 years ago.
  • The debt/assets ratio for TBI is higher compared to a year ago.
TBI Yearly Shares OutstandingTBI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
TBI Yearly Total Debt VS Total AssetsTBI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 3.48 indicates that TBI is not in any danger for bankruptcy at the moment.
  • TBI's Altman-Z score of 3.48 is fine compared to the rest of the industry. TBI outperforms 69.77% of its industry peers.
  • A Debt/Equity ratio of 0.24 indicates that TBI is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.24, TBI is in line with its industry, outperforming 52.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z 3.48
ROIC/WACCN/A
WACC9.22%
TBI Yearly LT Debt VS Equity VS FCFTBI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • TBI has a Current Ratio of 2.15. This indicates that TBI is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of TBI (2.15) is better than 77.91% of its industry peers.
  • A Quick Ratio of 2.15 indicates that TBI has no problem at all paying its short term obligations.
  • TBI has a Quick ratio of 2.15. This is in the better half of the industry: TBI outperforms 77.91% of its industry peers.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 2.15
TBI Yearly Current Assets VS Current LiabilitesTBI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. TBI Growth Analysis

3.1 Past

  • TBI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -53.33%.
  • TBI shows a small growth in Revenue. In the last year, the Revenue has grown by 3.10%.
  • TBI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.63% yearly.
EPS 1Y (TTM)-53.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1150%
Revenue 1Y (TTM)3.1%
Revenue growth 3Y-10.5%
Revenue growth 5Y-2.63%
Sales Q2Q%8.35%

3.2 Future

  • Based on estimates for the next years, TBI will show a very strong growth in Earnings Per Share. The EPS will grow by 67.63% on average per year.
  • TBI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.71% yearly.
EPS Next Y91.7%
EPS Next 2Y67.63%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.53%
Revenue Next 2Y4.71%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TBI Yearly Revenue VS EstimatesTBI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B 2.5B
TBI Yearly EPS VS EstimatesTBI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 2

More info and screens

Find the best growth stocksShow best growing peers

1

4. TBI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TBI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TBI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TBI Price Earnings VS Forward Price EarningsTBI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TBI Per share dataTBI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40 50

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TBI's earnings are expected to grow with 67.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.63%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TBI Dividend Analysis

5.1 Amount

  • TBI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TBI Fundamentals: All Metrics, Ratios and Statistics

TRUEBLUE INC

NYSE:TBI (4/10/2026, 8:04:00 PM)

After market: 3.35 +0.02 (+0.6%)

3.33

-0.13 (-3.76%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryProfessional Services
Earnings (Last)02-18
Earnings (Next)04-27
Inst Owners96.97%
Inst Owner Change0%
Ins Owners7.84%
Ins Owner Change25.7%
Market Cap100.10M
Revenue(TTM)1.62B
Net Income(TTM)-47.96M
Analysts80
Price Target7.91 (137.54%)
Short Float %6.61%
Short Ratio5.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-114.07%
Min EPS beat(2)-364.14%
Max EPS beat(2)136%
EPS beat(4)2
Avg EPS beat(4)-55.99%
Min EPS beat(4)-364.14%
Max EPS beat(4)136%
EPS beat(8)5
Avg EPS beat(8)-78.49%
EPS beat(12)7
Avg EPS beat(12)4.36%
EPS beat(16)10
Avg EPS beat(16)8.59%
Revenue beat(2)2
Avg Revenue beat(2)2.28%
Min Revenue beat(2)0.16%
Max Revenue beat(2)4.4%
Revenue beat(4)3
Avg Revenue beat(4)0.93%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)4.4%
Revenue beat(8)3
Avg Revenue beat(8)-0.59%
Revenue beat(12)4
Avg Revenue beat(12)-0.99%
Revenue beat(16)5
Avg Revenue beat(16)-0.95%
PT rev (1m)0%
PT rev (3m)-8.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-350%
EPS NY rev (1m)0%
EPS NY rev (3m)-121.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.06
P/FCF N/A
P/OCF N/A
P/B 0.36
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-2.45
FCFYN/A
OCF(TTM)-1.93
OCFYN/A
SpS53.76
BVpS9.13
TBVpS7.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.51%
ROE -17.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.76%
FCFM N/A
ROA(3y)-9.23%
ROA(5y)-3.13%
ROE(3y)-20.15%
ROE(5y)-7.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.19%
GM growth 5Y-0.94%
F-Score4
Asset Turnover2.53
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 54.34%
Cap/Sales 0.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 2.15
Altman-Z 3.48
F-Score4
WACC9.22%
ROIC/WACCN/A
Cap/Depr(3y)85.72%
Cap/Depr(5y)97.76%
Cap/Sales(3y)1.38%
Cap/Sales(5y)1.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1150%
EPS Next Y91.7%
EPS Next 2Y67.63%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.1%
Revenue growth 3Y-10.5%
Revenue growth 5Y-2.63%
Sales Q2Q%8.35%
Revenue Next Year5.53%
Revenue Next 2Y4.71%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year217.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-78.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-240.26%
OCF growth 3YN/A
OCF growth 5YN/A

TRUEBLUE INC / TBI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TRUEBLUE INC?

ChartMill assigns a fundamental rating of 3 / 10 to TBI.


What is the valuation status of TRUEBLUE INC (TBI) stock?

ChartMill assigns a valuation rating of 1 / 10 to TRUEBLUE INC (TBI). This can be considered as Overvalued.


How profitable is TRUEBLUE INC (TBI) stock?

TRUEBLUE INC (TBI) has a profitability rating of 1 / 10.


How financially healthy is TRUEBLUE INC?

The financial health rating of TRUEBLUE INC (TBI) is 5 / 10.


Can you provide the expected EPS growth for TBI stock?

The Earnings per Share (EPS) of TRUEBLUE INC (TBI) is expected to grow by 91.7% in the next year.